A gold miner's shares surged 5%, driven by strong gains in its NYSE shares and a bullish note from UBS, which highlighted the company's stock as a top choice for ASX gold exposure amid rising gold ...

PYC Therapeutics Ltd held its Q3 2025 earnings call, emphasizing its pipeline development and strategic market opportunities rather than specific financial results. The company’s stock saw a minor ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...

The secondary aim of the trial is to assess the drug’s efficacy when the trial extends to polycystic kidney disease patients in the second half of this year. Credit: SewCreamStudio / Shutterstock. · ...

Barrenjoey’s research department initiated on PYC Therapeutics last month in hopes of strengthening its relationship with the budding biotech. But the inhabitants of the Vertical Village only had to ...

The last three months have been tough on PYC Therapeutics Limited (ASX:PYC) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the returns ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

There's nothing the Legend of Zelda community is incapable of, it seems, and decompiling the original Majora's Mask game for fellow fans looking to mod, speedrun, or simply learn about the code is no ...